The World Health Organization (WHO) has included two more of Aurobindo Pharma's anti-retroviral products viz. nevirapine oral suspension 50 mg / 5 ml and stavudine for oral solution 1 mg / ml in the pre-qualification list.

According to a company release, this inclusion takes the count of the company's products in the pre-qualification list to twelve. This is the first time that a generic version of nevirapine oral suspension and stavudine for oral solution has appeared on the pre-qualification list. Both these products are used as a part of first line treatment in paediatric AIDS.